Background: Asymmetric dimethylarginine (ADMA) is an emerging
biomarker that has been associated with oxidative metabolism and increased
cardiovascular risk. Little information is available regarding the effect of
diet on ADMA. Methods: The authors studied 86 overweight/obese adults
as part of a clinical trial of psyllium supplementation to determine whether 3
months of such supplementation would affect ADMA levels. Forty-one people in
the intervention group received 14 g/day of psyllium in addition to their
usual diet compared with 45 controls who followed their usual diet alone. The
2 groups were comparable at baseline in demographic characteristics and body
mass index. Results: Baseline ADMA levels were elevated in this
overweight/obese population compared with published reference values in
healthy individuals (0.75 vs 0.50 μmol/L). The change in ADMA levels over 3
months was not different in the psyllium group compared with the control group
(–.03 vs –.01 μmol/L, P = .73). Conclusions:
These findings do not support a significant effect of psyllium fiber
supplementation on ADMA.
Böger RH, Ron EY. L-Arginine improves vascular function by
overcoming the deleterious effects of ADMA, a novel cardiovascular risk
factor. Altern Med Rev.2005
;10:14
-23.
3.
Kaliora AC, Dedoussis GV. Natural antioxidant compounds in risk
factors for CVD. Pharmacol Res.2007
;56:99
-109.
4.
Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship
between obesity, smoking, and the endogenous nitric oxide synthase inhibitor,
asymmetric dimethylarginine. Metabolism.2004
;53:1574
-1579.
5.
Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine
is an independent risk factor for coronary heart disease: results from the
multicenter Coronary Artery Risk Determination Investigating the Influence of
ADMA Concentration (CARDIAC) study. Am Heart J.2006
;152:493.e1
-493.e8.
6.
Krzyzanowska K, Mittelmayer F, Woltz M, Schernthaner G. Asymmetric
dimethylarginine predicts cardiovascular events in patients with type 2
diabetes. Diabetes Care.2007
;30:1834
-1839.
7.
Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated
plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in
early diabetic nephropathy in type 1 diabetes. Diabetes
Care. 2004;27:765
-769.
8.
Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C.
Prognostic value of combined use of biomarkers of inflammation, endothelial
dysfunction, and myocardiopathy in patients with ESRD. Kidney
Int. 2005;67:2330
-2337.
9.
Böger RH. The emerging role of asymmetric dimethylarginine as
a novel cardiovascular risk factor. Cardiovasc Res.2003
;59:824
-833.
10.
O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia
(postprandial dysmetabolism) is a cardiovascular risk factor. Am J
Cardiol. 2007;100:899
-904.
11.
King DE, Egan BM, Geesey M. Relation of dietary fat and fiber to
elevation of C-reactive protein [erratum in: Am J Cardiol.
2004;93:812]. Am J Cardiol.2003
;92:1335
-1339.
12.
Mittal G, Vadhera S, Brar AP, Soni G. Protective role of dietary
fibre on N-nitrosopyrrolidine-induced toxicity in hypercholesterolemic rats.
Hum Exp Toxicol.2007
;26:91
-98.
13.
Wells BJ, Mainous AG III, Everett CJ. Association between dietary
arginine and C-reactive protein. Nutrition.2005
;21:125
-130.
14.
Theuwissen E, Mensink RP. Water-soluble dietary fibers and
cardiovascular disease. Physiol Behav.2008
;94:285
-292.
15.
King DE. Dietary fiber, inflammation, and cardiovascular disease.
Mol Nutr Food Res.2005
;49:594
-600.
16.
Salas-Salvado J, Bullo M, Perez-Heras A, Ros E. Dietary fibre, nuts
and cardiovascular diseases. Br J Nutr.2006
;96(suppl 2):S46
-S51.
17.
Ignarro LJ, Balestrieri ML, Napoli C. Nutrition, physical activity,
and cardiovascular disease: an update. Cardiovasc Res.2007
;73:326
-340.
18.
King DE, Mainous AG III, Egan BM, Woolson RF, Geesey ME. Effect of
psyllium fiber supplementation on C-reactive protein: the trial to reduce
inflammatory markers (TRIM). Ann Fam Med.2008
;6:100
-106.
19.
Albert MA, Ridker PM. C-reactive protein as a risk predictor: do
race/ethnicity and gender make a difference?
Circulation.2006
;114(5):67
-74.
20.
Eid HM, Arneson H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship
between obesity, smoking, and the endogenous nitric oxide synthase inhibitor
asymmetric dimethylarginine. Metabolism.2004
;53:1574
-1579.
21.
Khera A, McGuire DK, Murphy SA, et al. Race and gender differences
in C-reactive protein levels. J Am Coll Cardiol.2005
;46:464
-469.
22.
Diaz VA, Mainous AG III, Koopman RJ, Carek PJ, Geesey ME. Race and
diet in the overweight: association with cardiovascular risk in a nationally
representative sample. Nutrition.2005
;21:718
-725.
23.
Schulze F, Wesemann R, Schwedhelm E, et al. Determination of
asymmetric dimethylarginine (ADMA) by a novel ELISA assay. Clin
Chem Lab Med. 2004;42:1377
-1383.
24.
Smith CL, Vallance P. Cardiovascular tests: use & limits of
biochemical markers—therapeutic measurements of ADMA involved in
cardiovascular disorders. Curr Pharm Design.2005
;11:2177
-2185.
25.
Martens-Lobenhoffer J, Bode-Böger SM. Simultaneous detection
of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and
citrulline in human plasma and urine applying liquid chromatography-mass
spectrometry with very straightforward sample preparation. J
Chromatogr B Analyt Technol Biomed Life Sci.2003
;798:231
-239.
26.
Garcia RG, Perez M, Maas R, Schwedhelm E, Boger RH, Lopez-Jaramillo
P. Plasma concentrations of ADMA in metabolic syndrome. Int J
Cardiol. 2006;122:176
-178.
27.
Eid HM, Arnesen H, Hjerkinn EM, Lybert T, Ellingsen I, Seljeflot I.
Effect of diet and omega-3 fatty acid intervention on asymmetric
dimethylarginine. Nutr Metab (Lond).2006
;3:4
.
28.
Zoccali C, Bode-Böger SM, Mallamaci F, et al. Asymmetric
dimethyl-arginine (ADMA): an endogenous inhibitor of nitric oxide synthase
predicts mortality in end-stage renal disease (ESRD).
Lancet. 2001;358:2113
-2117.
